Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters
about
Should we treat acute HIV infection?When to start antiretroviral therapy: as soon as possibleAge at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United StatesModeling of HIV-1 infection: insights to the role of monocytes/macrophages, latently infected T4 cells, and HAART regimesMortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaborationCan we trust the guidelines? Comparison between the data presented and the recommendations of the International Antiviral Society-USA PanelAssociations of HIV testing and late diagnosis at a Japanese university hospitalScaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005-2013.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialUsing CD4 percentage and age to optimize pediatric antiretroviral therapy initiationEstablishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odysseyEvolution of HIV treatment guidelines in high- and low-income countries: converging recommendationsAntiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era.Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.The undiagnosed HIV epidemic in France and its implications for HIV screening strategies.When to start antiretroviral therapy: the need for an evidence base during early HIV infectionCommunity perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.Comparison of HIV outcomes for patients linked at hospital versus community-based clinicsAntiretroviral therapy: when to startGuidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort studyInitiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.Efficacy of imidazolquinoline on treatment of condyloma acuminatum of the buccal mucosa.Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?HIV treatment as prevention and HPTN 052.Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings?Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/μL under routine program conditions in Uganda.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy?Neurologic Complications of Commonly Used Drugs in the Hospital Setting.Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy.
P2860
Q26826523-F49C72DA-EB40-4642-8D09-6EDA9DF967DEQ27006767-C87B7299-DF27-40E6-BCC8-EAF1D70FAEB4Q28387887-46E4892F-80AF-498C-8A4B-C6B1616D8D48Q28484046-E7A749B6-10E4-4472-9E1F-0EA55410B04DQ30583563-B2CFA730-DC91-4F0C-AFD6-C4EA23271273Q30869836-E569A3F2-8357-497A-B458-35C1FC9BF987Q33430425-5617B9C6-E67A-4C35-9370-55A52FAE8AB7Q33714596-2FED02BB-E921-4BA4-8D5D-5688B1FEEA6AQ33775397-F0D88DCA-75B9-43E9-8A03-17549ACE9EE3Q34086963-8B0F7C6C-E830-4E1A-99AB-0C42210D006FQ34263117-9715BE93-4C71-4103-AADD-C8657B82E9A5Q34280961-39F10ADC-FB4C-41DD-BD8D-AB250AE5EC63Q34321843-D9CAC63F-0E7A-45D5-B266-171E3FFC084BQ34379806-EF5C783E-437F-44BC-9981-455879F9603FQ34387168-67E70572-F46A-43FF-98C3-C997534163B6Q34485916-CF182347-A4ED-4C84-B15A-75CA86CF03D1Q34663606-3B8D79B8-4D70-465A-BC7C-F62DD9412C22Q34666498-8E639BF2-6D34-4DC2-864E-F9D591754986Q34676429-BA508DC0-E2F2-4FB4-9117-8DB28148E3E7Q34773308-05BD7AA4-3F0D-4514-AD12-2FABA2D5C1DEQ35124919-4D23F512-726C-4C5B-8C51-3962BF2749EDQ35142189-A6F32C96-DE61-4F54-9C17-F89C7BBA56A0Q35156672-93A44C74-10F0-49AA-B452-645EE60734FCQ35204279-0D8A5AD7-A02A-4043-A3FA-058CDE21F0EAQ35530299-A2223BC4-0A53-4FC1-A0FE-D31698682B6DQ35794099-FE347EC0-E9C4-407D-83A9-0BD91DB689C3Q36070585-1A93F2F7-3B21-4846-A095-97264925AD14Q36157811-78564292-FF8D-4559-95C3-3A56EF38C890Q36338387-E30A57AA-36D5-42D3-89AD-F40ABA635489Q36364604-6685B0D7-AE6E-4768-BEC0-F86E700A25F0Q36853880-086CE1B7-22CD-49DB-8765-50FAA85EB267Q37111627-7D331FAB-B1DB-4832-AF58-D74656185261Q37167877-8FAB4057-C1C4-4EE7-80D9-83DC7BC1A63AQ37220792-F15DAD8F-0B21-4916-8F3F-69ED2032F7A3Q37418140-078C2E1E-9DDF-462F-BF09-55BB66AF997BQ37518294-4B23E8EF-67FD-4B03-9D82-E2145FDDF756Q37554064-F5B737AD-0748-4A1B-877E-0C687280085EQ38422291-13B49954-C698-49B3-93AE-00FD5D2E7885Q38746169-2901D8BD-A26E-4DEA-8B8B-076D6F1BE635Q39708436-CEF7D674-9A95-462B-87E2-6D536AEAE403
P2860
Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Timing of HAART initiation and ...... cy virus type 1 seroconverters
@en
Timing of HAART initiation and ...... y virus type 1 seroconverters.
@nl
type
label
Timing of HAART initiation and ...... cy virus type 1 seroconverters
@en
Timing of HAART initiation and ...... y virus type 1 seroconverters.
@nl
prefLabel
Timing of HAART initiation and ...... cy virus type 1 seroconverters
@en
Timing of HAART initiation and ...... y virus type 1 seroconverters.
@nl
P2860
P1476
Timing of HAART initiation and ...... cy virus type 1 seroconverters
@en
P2093
Writing Committee for the CASCADE Collaboration
P2860
P304
P356
10.1001/ARCHINTERNMED.2011.401
P407
P577
2011-09-01T00:00:00Z